Danielle Debussey McCallion, FNP-C

Danielle McCallion practices at Sharp Memorial Hospital in San Diego, California, part of Sharp HealthCare.

Danielle McCallion's NPI, 1568060622, was assigned on October 12, 2020. Danielle McCallion holds California license 95015530.

Danielle McCallion's primary practice is Sharp Memorial Hospital, at 7901 Frost St, San Diego, CA 92123 in San Diego County. The practice phone is (858) 939-3400.

Danielle McCallion's primary practice is Sharp Memorial Hospital in San Diego, California, part of Sharp HealthCare. The medical group on file is Balboa Nephrology. Dmand AI also links Danielle McCallion to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Danielle McCallion practices, 2 sites in all. Vendor and product names are available with a free account.

Family is Danielle McCallion's primary specialty in the NPI Registry, under taxonomy code 363LF0000X. Danielle McCallion is licensed in California.

CMS data shows 98 Medicare services from Danielle McCallion across 3 procedure codes in 2024, for 59 Medicare patients. Medicare paid $16,027 for them. Every service was in an office.

CMS counts 59 Medicare patients who saw Danielle McCallion in 2024. The largest group is 65 to 74, with 26 patients. 75% of them have chronic kidney disease, and 75% have diabetes. Their average risk score is 10.72, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Danielle McCallion's median patient age at 56, with 44% women.

In 2024, Danielle McCallion wrote 863 Medicare Part D claims for 150 patients. 84% of them were for generic drugs. CMS names the drug for 692 of them, across 18 drugs with 11 or more claims each, at $329,786 in total drug cost.

Danielle McCallion accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

CMS Open Payments shows 2 general payments to Danielle McCallion from 2 drug and device companies from 2024 to 2025. Education make up the largest share, 67% of the total. Veloxis Pharmaceuticals, Inc. paid the most, $68.